AU753547B2 - Substituted tricyclics - Google Patents

Substituted tricyclics Download PDF

Info

Publication number
AU753547B2
AU753547B2 AU23819/99A AU2381999A AU753547B2 AU 753547 B2 AU753547 B2 AU 753547B2 AU 23819/99 A AU23819/99 A AU 23819/99A AU 2381999 A AU2381999 A AU 2381999A AU 753547 B2 AU753547 B2 AU 753547B2
Authority
AU
Australia
Prior art keywords
methyl
acid
carbamoylcarbazol
oxyacetic acid
ylloxyacetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU23819/99A
Other languages
English (en)
Other versions
AU2381999A (en
Inventor
Benjamin Alan Anderson
Nicholas James Bach
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Kinnick
Ho-Shen Lin
Richard James Loncharich
John NcNeill McGill III
Edward David Mihelich
John Michael Morin Jr.
Michael Leroy Phillips
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Richard Walter Schevitz
Robert Theodore Vasileff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2381999A publication Critical patent/AU2381999A/en
Application granted granted Critical
Publication of AU753547B2 publication Critical patent/AU753547B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU23819/99A 1998-04-17 1999-04-16 Substituted tricyclics Ceased AU753547B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17
US09/062328 1998-04-17

Publications (2)

Publication Number Publication Date
AU2381999A AU2381999A (en) 1999-10-28
AU753547B2 true AU753547B2 (en) 2002-10-24

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
AU23819/99A Ceased AU753547B2 (en) 1998-04-17 1999-04-16 Substituted tricyclics
AU23817/99A Ceased AU753436B2 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU23817/99A Ceased AU753436B2 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Country Status (30)

Country Link
EP (2) EP0950657B1 (enExample)
JP (2) JP4435330B2 (enExample)
KR (2) KR100586761B1 (enExample)
CN (1) CN1149193C (enExample)
AR (2) AR018593A1 (enExample)
AT (2) ATE271037T1 (enExample)
AU (2) AU753547B2 (enExample)
BR (2) BR9902365A (enExample)
CA (2) CA2269246C (enExample)
CO (2) CO5031247A1 (enExample)
CZ (2) CZ136999A3 (enExample)
DE (2) DE69917833T2 (enExample)
DK (1) DK0950657T3 (enExample)
DZ (1) DZ2769A1 (enExample)
EA (2) EA002347B1 (enExample)
ES (2) ES2222663T3 (enExample)
HU (2) HUP9901220A3 (enExample)
ID (2) ID23287A (enExample)
IL (2) IL129483A0 (enExample)
NO (2) NO314400B1 (enExample)
NZ (3) NZ507564A (enExample)
PE (2) PE20000476A1 (enExample)
PL (2) PL332566A1 (enExample)
PT (1) PT950657E (enExample)
SG (2) SG81976A1 (enExample)
SI (1) SI0950657T1 (enExample)
TR (2) TR199900843A2 (enExample)
TW (1) TWI238160B (enExample)
YU (2) YU19199A (enExample)
ZA (2) ZA992771B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
WO2002000256A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
WO2002000255A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
US6933313B2 (en) 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
CA2719721C (en) 2008-03-26 2012-12-18 Daiichi Sankyo Company, Limited Tetrahydroisoquinoline derivative
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2531511A1 (en) 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CN104797559A (zh) * 2012-11-30 2015-07-22 通用电气健康护理有限公司 卤化锌介导的环化过程得到三环吲哚
CN111362863A (zh) 2012-11-30 2020-07-03 通用电气健康护理有限公司 三环吲哚衍生物的结晶方法
EP3248230B1 (de) * 2015-01-20 2020-05-06 cynora GmbH Verwendung organischer moleküle in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
CA2304482A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
CA2269246C (en) 2009-08-25
AU753436B2 (en) 2002-10-17
BR9902365A (pt) 2001-04-24
PL332566A1 (en) 1999-10-25
IL129485A0 (en) 2000-02-29
EA199900301A3 (ru) 2000-04-24
YU18999A (sh) 2002-08-12
EA199900303A2 (ru) 1999-10-28
EP0952149A2 (en) 1999-10-27
ATE268756T1 (de) 2004-06-15
NO991822L (no) 1999-10-18
PT950657E (pt) 2004-11-30
CO5031247A1 (es) 2001-04-27
CA2269246A1 (en) 1999-10-17
EP0950657B1 (en) 2004-07-14
HUP9901221A3 (en) 2001-11-28
DE69917833T2 (de) 2005-07-14
EA002816B1 (ru) 2002-10-31
CN1253948A (zh) 2000-05-24
NO991822D0 (no) 1999-04-16
NZ507564A (en) 2002-10-25
HUP9901220A3 (en) 2001-11-28
PE20000432A1 (es) 2000-05-23
NO991821D0 (no) 1999-04-16
AU2381799A (en) 1999-10-28
SI0950657T1 (en) 2005-02-28
PL332565A1 (en) 1999-10-25
JP2000026416A (ja) 2000-01-25
HU9901221A (hu) 2000-04-28
NZ335253A (en) 2000-11-24
CN1149193C (zh) 2004-05-12
DE69917833D1 (de) 2004-07-15
ES2222663T3 (es) 2005-02-01
ATE271037T1 (de) 2004-07-15
JP4435330B2 (ja) 2010-03-17
ES2226286T3 (es) 2005-03-16
EP0952149A3 (en) 2001-08-16
DE69918590T2 (de) 2005-07-21
NO312240B1 (no) 2002-04-15
TR199900853A3 (tr) 1999-11-22
AU2381999A (en) 1999-10-28
IL129483A0 (en) 2000-02-29
EP0952149B1 (en) 2004-06-09
HU9901220A (hu) 2000-04-28
AR018186A1 (es) 2001-10-31
ZA992771B (en) 2002-04-18
EP0950657A2 (en) 1999-10-20
ID23287A (id) 2000-04-05
NZ335251A (en) 2000-11-24
YU19199A (sh) 2002-08-12
DK0950657T3 (da) 2004-11-22
JPH11322713A (ja) 1999-11-24
HU9901220D0 (en) 1999-06-28
ZA992772B (en) 2002-07-16
DE69918590D1 (de) 2004-08-19
TR199900853A2 (xx) 1999-11-22
BR9901279A (pt) 2000-05-02
AR018593A1 (es) 2001-11-28
NO314400B1 (no) 2003-03-17
CZ137099A3 (cs) 1999-11-17
CO5011054A1 (es) 2001-02-28
EA199900301A2 (ru) 1999-10-28
KR19990083232A (ko) 1999-11-25
HU9901221D0 (en) 1999-06-28
TR199900843A2 (xx) 2000-02-21
SG81976A1 (en) 2001-07-24
TWI238160B (en) 2005-08-21
CZ136999A3 (cs) 1999-11-17
PE20000476A1 (es) 2000-06-02
EP0950657A3 (en) 2001-08-16
SG81977A1 (en) 2001-07-24
CA2269262A1 (en) 1999-10-17
DZ2769A1 (fr) 2003-12-01
KR100586761B1 (ko) 2006-06-08
KR19990083233A (ko) 1999-11-25
NO991821L (no) 1999-10-18
EA002347B1 (ru) 2002-04-25
EA199900303A3 (ru) 2000-04-24
ID23761A (id) 2000-05-11

Similar Documents

Publication Publication Date Title
AU2381999A (en) Substituted tricyclics
US6177440B1 (en) Substituted tricyclics
JP4119745B2 (ja) シクロペンタノインドール類、この化合物を含む組成物および治療方法
AU734096B2 (en) Substituted tricyclics
JP2001503055A5 (enExample)
JP4435325B2 (ja) 置換三環式化合物およびそれを含有する組成物
JP2002530268A (ja) ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体
JP2025508475A (ja) プロスタグランジンｅ２（ｐｇｅ２）受容体拮抗剤としてのアミド化合物
JP2005527464A (ja) ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
US6713645B1 (en) Substituted tricyclics
JP2005527466A (ja) ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
JP2004518659A5 (enExample)
JP2004518659A (ja) 新規ｓＰＬＡ２インヒビター
US6933313B2 (en) Substituted carbazoles as inhibitors of sPLA2
WO2001036420A1 (en) Tricyclic azaindolizine derivatives having an spla2- inhibiting effect
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HK1024912A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HK40029463A (en) Pyrazine derivative and application thereof in inhibiting shp2
HK40029463B (en) Pyrazine derivative and application thereof in inhibiting shp2
JP2004520363A (ja) 新規なｓＰＬＡ２インヒビター
JP2004523504A (ja) 新規なｓＰＬＡ２インヒビター
JPWO2001036420A1 (ja) ｓＰＬＡ２阻害作用を有する三環性アザインドリジン誘導体
HUP9903545A2 (hu) Helyettesített triciklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)